Arri Coomarasamy, Adam J Devall, Jan J Brosens, Siobhan Quenby, Mary D Stephenson, Sony Sierra, Ole B Christiansen, Rachel Small, Jane Brewin, Tracy E Roberts, Rima Dhillon-Smith, Hoda Harb, Hannah Noordali, Argyro Papadopoulou, Abey Eapen, Matt Prior, Gian Carlo Di Renzo, Kim Hinshaw, Ben W Mol, Mary Ann Lumsden, Yacoub Khalaf, Andrew Shennan, Mariette Goddijn, Madelon van Wely, Maya Al-Memar, Phil Bennett, Tom Bourne, Raj Rai, Lesley Regan, Ioannis D Gallos
Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone supplementation may reduce the risk of miscarriage in women with recurrent or threatened miscarriage. Cochrane Reviews summarized the evidence and found that the trials were small with substantial methodologic weaknesses. Since then, the effects of first-trimester use of vaginal micronized progesterone have been evaluated in 2 large, high-quality, multicenter placebo-controlled trials, one targeting women with unexplained recurrent miscarriages (the PROMISE [PROgesterone in recurrent MIScarriagE] trial) and the other targeting women with early pregnancy bleeding (the PRISM [PRogesterone In Spontaneous Miscarriage] trial)...
August 2020: American Journal of Obstetrics and Gynecology